Literature DB >> 8962201

Efficacy of fludarabine as an immunosuppressor for bone marrow transplantation conditioning: preliminary results.

A Terenzi1, C Aristei, F Aversa, K Perruccio, F Chionne, C Raymondi, P Latini, M F Martelli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8962201

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  17 in total

1.  Reduced-toxicity conditioning therapy with allogeneic stem cell transplantation for acute leukemia.

Authors:  Borje S Andersson; Marcos de Lima; Peter F Thall; Timothy Madden; James A Russell; Richard E Champlin
Journal:  Curr Opin Oncol       Date:  2009-06       Impact factor: 3.645

Review 2.  Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies.

Authors:  Benigno C Valdez; Borje S Andersson
Journal:  Environ Mol Mutagen       Date:  2010-07       Impact factor: 3.216

3.  Haploidentical stem cell transplantation for acute leukemia.

Authors:  F Aversa; A Terenzi; R Felicini; A Carotti; F Falcinelli; A Tabilio; A Velardi; M F Martelli
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

4.  Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.

Authors:  Borje S Andersson; Benigno C Valdez; Marcos de Lima; Xuemei Wang; Peter F Thall; Laura L Worth; Uday Popat; Timothy Madden; Chitra Hosing; Amin Alousi; Gabriela Rondon; Partow Kebriaei; Elizabeth J Shpall; Roy B Jones; Richard E Champlin
Journal:  Biol Blood Marrow Transplant       Date:  2010-10-11       Impact factor: 5.742

Review 5.  Transplantation of haploidentically mismatched stem cells for the treatment of malignant diseases.

Authors:  Franco Aversa; Massimo F Martelli
Journal:  Springer Semin Immunopathol       Date:  2004-09-11

Review 6.  Promising role of reduced-toxicity hematopoietic stem cell transplantation (PART-I).

Authors:  S Abdul Wahid Fadilah; Md Pazil Aqilah
Journal:  Stem Cell Rev Rep       Date:  2012-12       Impact factor: 5.739

7.  Defining the intensity of conditioning regimens: working definitions.

Authors:  Andrea Bacigalupo; Karen Ballen; Doug Rizzo; Sergio Giralt; Hillard Lazarus; Vincent Ho; Jane Apperley; Shimon Slavin; Marcelo Pasquini; Brenda M Sandmaier; John Barrett; Didier Blaise; Robert Lowski; Mary Horowitz
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-01       Impact factor: 5.742

8.  Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.

Authors:  Borje S Andersson; Marcos de Lima; Peter F Thall; Xuemei Wang; Daniel Couriel; Martin Korbling; Soonja Roberson; Sergio Giralt; Betty Pierre; James A Russell; Elizabeth J Shpall; Roy B Jones; Richard E Champlin
Journal:  Biol Blood Marrow Transplant       Date:  2008-06       Impact factor: 5.742

Review 9.  Fifty years of melphalan use in hematopoietic stem cell transplantation.

Authors:  Ulas D Bayraktar; Qaiser Bashir; Muzaffar Qazilbash; Richard E Champlin; Stefan O Ciurea
Journal:  Biol Blood Marrow Transplant       Date:  2012-08-24       Impact factor: 5.742

Review 10.  Busulfan in hematopoietic stem cell transplantation.

Authors:  Stefan O Ciurea; Borje S Andersson
Journal:  Biol Blood Marrow Transplant       Date:  2009-02-12       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.